Bintex Futures (BNTX) news

Akari Therapeutics appoints Vatnak Vat-Ho chief business officer

US Stock Market Movement: BioNTech plunges on October 13 as BNT113 fails to meet PFS endpoint

BioNTech's Phase 2/3 Trial of BNT113 in Head, Neck Cancer Fails to Meet Progression-Free Survival Endpoint

A COVID Vaccine Stock on the S&P 500 Is Up 600% This Year

Biontech Insider Sold Shares Worth $5,945,855, According to a Recent SEC Filing

04:53 PM EDT, 10/09/2026 (MT Newswires) -- Ugur Sahin, 10% Owner, Chief Executive Officer, on October 08, 2026, sold 63,209 shares in Biontech (BNTX) for $5,945,855. Following the Form 4 filing with the SEC, Sahin has control over a total of 39,218,111 ordinary shares of the company, with 39,218,111 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1776985/000212397526000035/xslF345X05/wk-form4_1791578831.xml

BioNTech CEO Ugur Sahin disposes of $5,935,923 of common shares

BioNTech CEO Ugur Sahin disclosed sales of ordinary shares on Oct. 8-9, 2026. Disposed of 63,209 shares at USD 92.3142 to USD 95.3733. Directly held ordinary shares fell to zero following the transactions. Continued to report 39,218,111 ordinary shares held indirectly. Trades were executed under a Rule 10b5-1 plan adopted on June 3, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioNTech SE published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0002123975-26-000035), on October 09, 2026, and is solely responsible for the information contained therein.

Sector Update: Healthcare Stocks Gain Late Afternoon

03:57 PM EDT, 10/09/2026 (MT Newswires) -- Healthcare stocks rose late Friday afternoon, with the NYSE Healthcare Index up 1.2% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.6%. The iShares Biotechnology ETF (IBB) climbed 2.8%. In corporate news, Humana (HUM) shares surged 12% after it affirmed its full-year 2026 guidance of at least $9 in adjusted earnings per common share. Humana also said Friday that 95% of its Medicare Advantage members are enrolled in plans with ratings of at least four stars by the Centers for Medicare and Medicaid Services for 2027, which it called a "significant improvement." Shares of Moderna (MRNA) and other vaccine developers rose after The New York Times reported that the US National Institutes of Health is part of a public-private partnership to accelerate the development of cancer vaccines. Moderna shares jumped 12%. Merck (MRK), Novavax (NVAX) and BioNTech (BNTX) shares were up 2.6%, 17% and 5.3%, respectively. Vaxcyte (PCVX) and Vir Biotechnology (VIR) shares popped 10% and 5.6%, respectively. Brookdale Senior Living (BKD) shares were falling 5.2%. The company's weighted average occupancy rose sequentially but at a slower rate in September, resulting in Q3 occupancy coming in "slightly below" estimates, RBC Capital Markets said in a note emailed Friday. TRex Bio (TRXB) shares were up 1.4% after the company's Nasdaq debut. The biotech company priced its initial public offering of around 8.3 million common shares at $14 apiece for gross proceeds of $116.7 million.

Sector Update: Healthcare Stocks Gain Friday Afternoon

01:50 PM EDT, 10/09/2026 (MT Newswires) -- Healthcare stocks rose Friday afternoon, with the NYSE Healthcare Index up 1.2% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.6%. The iShares Biotechnology ETF (IBB) climbed 3%. In corporate news, Humana (HUM) shares surged nearly 12% after it affirmed its full-year 2026 guidance of at least $9 in adjusted earnings per common share. Humana also said Friday that 95% of its Medicare Advantage members are enrolled in plans with ratings of at least four stars by the Centers for Medicare and Medicaid Services for 2027, which it called a "significant improvement." Shares of Moderna (MRNA) and other vaccine developers rose after The New York Times reported that the US National Institutes of Health is part of a public-private partnership to accelerate the development of cancer vaccines. Moderna shares jumped 12%. Merck (MRK), Novavax (NVAX) and BioNTech (BNTX) shares were up 3%, 15% and 5.2%, respectively. Vaxcyte (PCVX) and Vir Biotechnology (VIR) shares popped nearly 9% and 6%, respectively. TRex Bio (TRXB) shares were down 2.5% after the company's Nasdaq debut. The biotech company priced its initial public offering of around 8.3 million common shares at $14 apiece for gross proceeds of $116.7 million.

Sector Update: Healthcare

01:18 PM EDT, 10/09/2026 (MT Newswires) -- Healthcare stocks gained Friday afternoon, with the NYSE Healthcare Index rising 1.1% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.5%. The iShares Biotechnology ETF (IBB) climbed 2.8%. In corporate news, shares of Moderna (MRNA) and other vaccine developers rose after The New York Times reported that the US National Institutes of Health is part of a public-private partnership to accelerate the development of cancer vaccines. Moderna shares jumped 11%. Merck (MRK), Novavax (NVAX) and BioNTech (BNTX) shares were up 2.4%, 13% and 4.9%, respectively. Vaxcyte (PCVX) and Vir Biotechnology (VIR) shares popped 8.5% and 6.3%, respectively.

Top Midday Stories: Delta Shares Fall After Q3 EPS, Revenue Misses; Apple Reportedly Cuts iPhone 18 Pro Component Orders Due to Soft Demand

12:14 PM EDT, 10/09/2026 (MT Newswires) -- All three major US stock indexes were up in late-morning trading Friday, as tech stocks took a step up. In company news, Delta Air Lines (DAL) reported Q3 adjusted earnings Friday of $1.72 per diluted share, up from $1.70 a year earlier but below the FactSet consensus analyst estimate of $1.77. Total Q3 adjusted revenue was $17.59 billion, up from $15.20 billion a year ago but below the FactSet consensus of $17.65 billion. For 2026, Delta expects adjusted EPS of $5.10 to $5.60, down from its prior estimate of $6.50 to $7.50 and compared with the FactSet expectation of $5.51. For Q4, the company expects adjusted EPS of $1.15 to $1.65 and revenue growth of around 20%. Analysts expect non-GAAP EPS of $1.43 on revenue of $17.24 billion. Delta shares were down 1.9% around midday. Apple (AAPL) has asked some suppliers to cut production of components for its iPhone 18 Pro and Pro Max models, Nikkei Asia reported Friday, citing people familiar with the matter. October orders were down by at least 15% from initial requests amid rising memory chip costs and weaker demand, the report said. Apple shares were down 1.8%. SpaceX (SPCX) said Thursday it agreed to acquire a nationwide portfolio of licenses covering up to 14 megahertz of paired spectrum in the 800 MHz band to expand Starlink Mobile's coverage in the US. The move could put pressure on wireless carriers, according to media reports. SpaceX shares were up 1.6%, while shares of AT&T (T), Verizon Communications (VZ) and T-Mobile US (TMUS) were down 9.8%, 9.9% and 12.8%, respectively. Humana (HUM) said Friday that 95% of its Medicare Advantage members are enrolled in plans with ratings of at least four stars by the Centers for Medicare and Medicaid Services for 2027, which it called a "significant improvement." CVS Health's (CVS) Aetna said over 69% of its MA members are in 2027 plans rated four stars or higher, while Alignment Healthcare (ALHC) said six of seven eligible MA contracts earned at least four stars. Humana shares we

European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading; Flat for Week

11:14 AM EDT, 10/09/2026 (MT Newswires) -- European equities traded in the US as American depositary receipts were tracking higher late Friday morning, rising 0.42% to 1,881.24 on the S&P Europe Select ADR Index, which is little changed for the week so far. From continental Europe, the gainers were led by biotech firm BioNTech (BNTX) and telecommunications company Nokia (NOK), which rose 2.6 % and 2.3% respectively. They were followed by medical device maker EDAP TMS (FOCL), which was up 2.3%, and internet browser company Opera (OPRA), 1.7% higher. The decliners from continental Europe were led by 3D printer company Materialise (MTLS) and brewing company Anheuser-Busch InBev (BUD), which fell 3% and 0.5% respectively. They were followed by biopharmaceutical company argenx (ARGX) and lender ING (ING), which were down 0.3% and 0.2% respectively. The gainers from the UK were led by biotech firm Trinity Biotech (TRIB) and pharmaceutical company Silence Therapeutics (SLN), which climbed 11% and 6% respectively. They were followed by biopharmaceutical company Akari Therapeutics (AKTX) and software firm Endava (DAVA), which increased 2.1% and 2% respectively. The decliners from the UK and Ireland were led by biopharmaceutical company Biodexa Pharmaceuticals (BDRX) and telecommunications operator Vodafone (VOD), which dropped 6.2% and 4.8% respectively. They were followed by utilities company National Grid (NGG) and alcoholic beverage company Diageo (DEO), which lost 1.2% and 0.4% respectively.

Market Chatter: Moderna, Other Vaccine Developer Stocks Rise as NIH Plans to Expedite Cancer Vaccines

10:57 AM EDT, 10/09/2026 (MT Newswires) -- Moderna (MRNA) and other vaccine developers were up on Friday after The New York Times reported that the National Institutes of Health is part of a public-private partnership to accelerate the development of cancer vaccines. Moderna shares were up 5.4% around 10:50 am ET, while shares of Merck (MRK) and Novavax (NVAX) were up 1.7% and 9.2%, respectively. Shares of BioNTech (BNTX), Vaxcyte (PCVX) and Vir Biotechnology (VIR) were up 2.5%, 5.7% and 3.1% (Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.) Price: 207.71, Change: +10.71, Percent Change: +5.44

--NIH Plans to Expedite Cancer Vaccines, NYT Reports; Vaccine Developer Shares Jump

10:48 AM EDT, 10/09/2026 (MT Newswires) -- Price: 211.48, Change: +14.48, Percent Change: +7.35

European Equities Traded in US as ADRs Fall in Thursday Trading

11:05 AM EDT, 10/08/2026 (MT Newswires) -- European equities traded in the US as American depositary receipts fell late Thursday morning with the S&P Europe Select ADR Index declining 0.3% to 1,870.68. From continental Europe, the gainers were led by petroleum refiner Equinor (EQNR) and oil and gas company Eni (E), which increased 3.1% and 3%, respectively. They were followed by medical device maker EDAP TMS (FOCL) and brewing company Anheuser-Busch InBev (BUD), which advanced 2.9% and 2.8%, respectively. The decliners from continental Europe were led by biopharmaceutical companies argenx (ARGX) and Cellectis (CLLS), which shed 14% and 3.7%, respectively. They were followed by telecommunications company Nokia (NOK) and biotech firm BioNTech (BNTX), which dropped 3.2% and 3%, respectively. The gainers from the UK and Ireland were led by oil and gas companies BP (BP) and Shell (SHEL), which rose 3.7% and 3.4%, respectively. They were followed by biopharmaceutical company Mereo BioPharma Group (MREO) and educational publisher Pearson (PSO), which were up 3.2% and 2%, respectively. The decliners from the UK and Ireland were led by biotech firm Trinity Biotech (TRIB) and biopharmaceutical company Biodexa Pharmaceuticals (BDRX), which lost 7.7% and 5.5%, respectively. They were followed by pharmaceutical company Silence Therapeutics (SLN) and biotech firm Autolus Therapeutics (AUTL), which dropped 5% and 3.6%, respectively.

Biontech Insider Sold Shares Worth $2,300,633, According to a Recent SEC Filing

05:17 PM EDT, 10/07/2026 (MT Newswires) -- Ugur Sahin, 10% Owner, Chief Executive Officer, on October 07, 2026, sold 24,000 shares in Biontech (BNTX) for $2,300,633. Following the Form 4 filing with the SEC, Sahin has control over a total of 39,281,320 ordinary shares of the company, with 63,209 shares held directly and 39,218,111 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1776985/000212397526000033/xslF345X05/wk-form4_1791407643.xml

BioNTech CEO Uğur Şahin disposes of 93,000 shares worth $9,031,514.30

BioNTech CEO Ugur Sahin sold 93,000 ordinary shares on Oct. 5-6, 2026. Sales priced at USD 97.2312 on Oct. 5, USD 96.8093 on Oct. 6. Direct holdings fell to 87,209 ordinary shares following the transactions. Filing also reports 39,218,111 ordinary shares held indirectly. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioNTech SE published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0002123975-26-000031), on October 06, 2026, and is solely responsible for the information contained therein.

S&P 500 Futures Climb In Premarket Trading; InterDigital, AGCO Lag

This article was automatically generated by Barrons.com using technology from Automated Insights. With U.S. stock markets set to open in two hours, Molson Coors Beverage Co. Cl A (TAP.A) was up 9.8% in pre-market trading, and Constellation Energy Corp. (CEG) was up 5.9%. Bio-Rad Laboratories Inc. Cl B (BIO.B), Cleveland-Cliffs Inc. (CLF), and Affiliated Managers Group Inc. (AMG) were all posting gains of at least 4%. In early trading, InterDigital Inc. (IDCC) and AGCO Corp. (AGCO) had posted declines, falling 12.8% and 7.0%, respectively. Meanwhile S&P 500 futures were up 0.39%, with futures for the Dow Jones Industrial Average rising 0.56%. The Cboe Volatility Index futures were down 1.97%. In commodities news, Brent crude oil futures were down 1.97%, while gold futures were up 0.84%. Bitcoin climbed 0.63% to $86,257. The 10-Year Treasury yield dropped to 5.269%. In the previous regular trading session, the S&P 500 and the Dow were up 0.66% and 0.18%, respectively. In Asia overnight, Japan's NIKKEI 225 Index was up 1.05%. In afternoon trading, stocks in Europe are up, with the STOXX Europe 600 Index rising 0.62% and the FTSE 100 Index increasing 0.40% from the previous close. U.S. stock markets open for trading at 9:30 a.m. ET. Data source: Dow Jones Market Data, FactSet. Data compiled October 06, 2026. This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. (END) Dow Jones Newswires October 06, 2026 07:30 ET (11:30 GMT)

Biontech Insider Sold Shares Worth $3,301,069, According to a Recent SEC Filing

BioNTech CEO Uğur Şahin disposes of $3,304,076 in common shares

European Equities Traded in the US as American Depositary Receipts Fall Sharply in Thursday Trading

BioNTech CEO Uğur Şahin disposes of $6.48 million in common shares

Pfizer (PFE.US), BioNTech (BNTX.US), and Moderna (MRNA.US) seek dismissal of Bayer’s Monsanto mRNA patent lawsuit, but the judge rejects the request

A federal judge in Delaware on Monday rejected the requests from Pfizer, BioNTech, and Moderna to dismiss a lawsuit filed against them by Monsanto, a subsidiary of the German pharmaceutical giant Bayer. The lawsuit concerns these pharmaceutical companies' use of a patent related to mRNA technology.

Pfizer (PFE.US), BioNTech (BNTX.US), and Moderna (MRNA.US) sought to dismiss Bayer's Monsanto mRNA patent lawsuit but were rejected by the judge.

Biontech Insider Sold Shares Worth $6,012,500, According to a Recent SEC Filing

BioNTech CEO Uğur Şahin disposes of USD 6,090,748 in common shares

Sector Update: Healthcare Stocks Advance Monday Afternoon

Market Chatter: BioNTech to Close 3 German Sites After Unsuccessful Sale Efforts

European Equities Traded in the US as American Depositary Receipts Edge Higher in Friday Trading; Down for Week

BioNTech CEO Uğur Şahin disposes of USD 6,850,514.3 in common shares

Biontech Insider Sold Shares Worth $7,860,757, According to a Recent SEC Filing